Undervalued Small Caps With Insider Buying

Results

63

8 new

Smaller, under-the-radar companies, backed by insider buying, presenting a compelling opportunity for investors seeking undervalued gems.

63 companies

	Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield	Industry
	UNB	US$25.49	5.5%	-7.7%	US$117.2m	n/a	1.3	n/a	5.6%	Banks
	APPN	US$26.03	-0.08%	-10.1%	US$1.9b	US$26.20	2159.2	108.9%	n/a	Software
	SHBI	US$23.12	2.1%	38.9%	US$769.8m	US$22.75	1.3	11.2%	2.1%	Banks
	FNLC	US$34.18	1.2%	28.9%	US$387.4m	n/a	1.3	n/a	4.3%	Banks
	GABC	US$47.99	1.7%	17.7%	US$1.8b	US$50.20	1.5	5.6%	2.6%	Banks
	KINS	US$19.91	-0.05%	27.6%	US$292.3m	US$21.50	9.3	20.8%	1.0%	Insurance
	BOTJ	US$26.60	2.0%	91.4%	US$121.4m	n/a	1.5	n/a	1.5%	Banks
	ANGX	US$4.32	5.6%	-66.8%	US$822.1m	US$8.00	2.1	59.6%	n/a	Media
	PEBO	US$39.50	3.3%	30.0%	US$1.4b	US$41.50	1.1	15.3%	4.3%	Banks
	PAX	US$11.14	0.4%	-17.4%	US$1.8b	US$15.57	24.5	34.3%	5.8%	Diversified Financials
	ILPT	US$9.20	3.0%	69.7%	US$572.0m	US$9.65	1.3	14.1%	2.2%	Real Estate
	MDV	US$18.27	4.1%	25.7%	US$216.9m	US$18.67	1.2	149.5%	6.6%	Real Estate
	SMWB	US$6.65	0.8%	-25.9%	US$586.0m	US$5.80	2.0	112.6%	n/a	Software
	ONT	US$19.41	-5.9%	-13.9%	US$715.9m	US$27.00	158.5	98.9%	n/a	Commercial Services
	RCEL New	US$5.09	26.6%	-12.4%	US$158.2m	US$9.07	2.2	64.1%	n/a	Pharmaceuticals & Biotech
	BMRC	US$28.85	2.1%	16.7%	US$457.1m	US$29.20	1.2	109.0%	3.5%	Banks
	EMYB	US$22.55	4.6%	40.1%	US$167.2m	n/a	1.3	n/a	2.1%	Banks
	ERII	US$8.62	-0.5%	-36.9%	US$437.1m	US$11.00	21.6	16.6%	n/a	Capital Goods
	MRBK	US$20.27	1.4%	35.8%	US$241.0m	US$23.00	1.2	21.5%	2.8%	Banks
	ANIK	US$15.16	-2.3%	37.8%	US$200.4m	US$17.50	1.7	67.6%	n/a	Pharmaceuticals & Biotech
	UMH	US$15.49	0.8%	-9.7%	US$1.3b	US$19.13	2.3	24.1%	5.8%	Real Estate
	PBHC New	US$16.00	-3.2%	6.4%	US$100.4m	n/a	0.8	n/a	2.5%	Banks
	TGEN	US$3.59	-10.5%	-48.8%	US$103.2m	US$8.83	4.1	119.5%	n/a	Capital Goods
	BY	US$38.12	2.5%	36.6%	US$1.7b	US$38.60	1.4	4.3%	1.3%	Banks

Page 1 of 2